BY-COVID - WP5 - Baseline Use Case: COVID-19 vaccine effectiveness assessment - Common Data Model Specification

Simon Saldner; Francisco Estupiñán-Romero; Nina Van Goethem; Marjan Meurisse; Javier González-Galindo; Enrique Bernal-Delgado; Lorenz Dolanski-Aghamanoukjan; Alexander Degelsegger-Marquez; Natalia Martínez-Lizaga

doi:10.5281/zenodo.6913046

BY-COVID - WP5 - Baseline Use Case: COVID-19 vaccine effectiveness assessment - Common Data Model Specification

Simon Saldner (Contributor), Francisco Estupiñán-Romero, Nina Van Goethem, Marjan Meurisse, Javier González-Galindo, Enrique Bernal-Delgado, Lorenz Dolanski-Aghamanoukjan (Contributor), Alexander Degelsegger-Marquez (Contributor), Natalia Martínez-Lizaga (Contributor)

DANS-KNAW

Research output: Other contribution › Scientific

Abstract

This publication corresponds to the Common Data Model (CDM) specification of the Baseline Use Case proposed in T.5.2 (WP5) in the BY-COVID project on “COVID-19 Vaccine(s) effectiveness in preventing SARS-CoV-2 infection.”

Research Question: “How effective have the SARS-CoV-2 vaccination programmes been in preventing SARS-CoV-2 infections?”

Intervention (exposure): COVID-19 vaccine(s)
Outcome: SARS-CoV-2 infection
Mediator: Vaccination schedule (type of vaccine)

Study Design: An observational retrospective longitudinal study to assess the effectiveness of the COVID-19 vaccine(s) in preventing SARS-CoV-2 infections using routinely collected social, health and care data from several countries.

A causal model was established using Directed Acyclic Graphs (DAGs) to map domain knowledge, theories and assumptions about the causal relationship between exposure and outcome. The DAG developed for the research question of interest is shown below.

Cohort definition: All people, eligible to be vaccinated (from 5 to 115 years old, included) or with, at least, one dose of a SARS-CoV-2 vaccine (any of the available brands) having or not a previous SARS-CoV-2 infection.

Inclusion criteria: All people vaccinated with at least one dose of the COVID-19 vaccine (any of the available brands) in an area of residence. Any person eligible to be vaccinated (from 5 to 115 years old, included) with a positive diagnosis (irrespective of the type of test) for SARS-CoV-2 infection (COVID-19) during the period of study.
Exclusion criteria: People not eligible for the vaccine (from 0 to 4 years old, included)
Study period: From the date of the first documented SARS-CoV-2 infection in each country to the most recent date in which data is available at the time of analysis. Roughly from 01-03-2020 to 30-06-2022, depending on the country.

Original language	English
Publisher	Zenodo
DOIs	https://doi.org/10.5281/zenodo.6913046
Publication status	Published - 27 Jul 2022

Keywords

COVID-19
comparative effectiveness
causal inference
international comparison
SARS-CoV-2
common data model
directed acyclic graph
synthetic data
vaccines

Access to Document

10.5281/zenodo.6913046Licence: CC BY

BY-COVID: BeYond COVID
Kalaitzi, V. (PI), Saldner, S. (Collaborator), Dillo, I. (Supervisor), Braukmann, R. (Advisor) & Hof, C. H. J. (Advisor)
01/10/2021 → 30/09/2024
Project: Research

BY-COVID Spring 2024 Baseline Use Case Workshop
Meurisse, M. (Organiser), Saldner, S. (Organiser), Kalaitzi, V. (Chair), Van Goethem, N. (Contributor), Bernal-Delgado, E. (Contributor) & Estupiñán-Romero, F. (Contributor)
06 Jun 2024
Activity: Participating in or organising an event › Workshop, seminar › Academic

Cite this

@misc{e531d96c09874a2cafa2dca96c0f1349,

title = "BY-COVID - WP5 - Baseline Use Case: COVID-19 vaccine effectiveness assessment - Common Data Model Specification",

abstract = "This publication corresponds to the Common Data Model (CDM) specification of the Baseline Use Case proposed in T.5.2 (WP5) in the BY-COVID project on “COVID-19 Vaccine(s) effectiveness in preventing SARS-CoV-2 infection.”Research Question: “How effective have the SARS-CoV-2 vaccination programmes been in preventing SARS-CoV-2 infections?” Intervention (exposure): COVID-19 vaccine(s) Outcome: SARS-CoV-2 infection Mediator: Vaccination schedule (type of vaccine)Study Design: An observational retrospective longitudinal study to assess the effectiveness of the COVID-19 vaccine(s) in preventing SARS-CoV-2 infections using routinely collected social, health and care data from several countries.A causal model was established using Directed Acyclic Graphs (DAGs) to map domain knowledge, theories and assumptions about the causal relationship between exposure and outcome. The DAG developed for the research question of interest is shown below.Cohort definition: All people, eligible to be vaccinated (from 5 to 115 years old, included) or with, at least, one dose of a SARS-CoV-2 vaccine (any of the available brands) having or not a previous SARS-CoV-2 infection. Inclusion criteria: All people vaccinated with at least one dose of the COVID-19 vaccine (any of the available brands) in an area of residence. Any person eligible to be vaccinated (from 5 to 115 years old, included) with a positive diagnosis (irrespective of the type of test) for SARS-CoV-2 infection (COVID-19) during the period of study. Exclusion criteria: People not eligible for the vaccine (from 0 to 4 years old, included) Study period: From the date of the first documented SARS-CoV-2 infection in each country to the most recent date in which data is available at the time of analysis. Roughly from 01-03-2020 to 30-06-2022, depending on the country. ",

keywords = "COVID-19, comparative effectiveness, causal inference, international comparison, SARS-CoV-2, common data model, directed acyclic graph, synthetic data, vaccines",

author = "Simon Saldner and Francisco Estupi{\~n}{\'a}n-Romero and {Van Goethem}, Nina and Marjan Meurisse and Javier Gonz{\'a}lez-Galindo and Enrique Bernal-Delgado and Lorenz Dolanski-Aghamanoukjan and Alexander Degelsegger-Marquez and Natalia Mart{\'i}nez-Lizaga",

year = "2022",

month = jul,

day = "27",

doi = "10.5281/zenodo.6913046",

language = "English",

publisher = "Zenodo",

address = "Switzerland",

type = "Other",

}

TY - GEN

T1 - BY-COVID - WP5 - Baseline Use Case: COVID-19 vaccine effectiveness assessment - Common Data Model Specification

AU - Estupiñán-Romero, Francisco

AU - Van Goethem, Nina

AU - Meurisse, Marjan

AU - González-Galindo, Javier

AU - Bernal-Delgado, Enrique

A2 - Saldner, Simon

A2 - Dolanski-Aghamanoukjan, Lorenz

A2 - Degelsegger-Marquez, Alexander

A2 - Martínez-Lizaga, Natalia

PY - 2022/7/27

Y1 - 2022/7/27

N2 - This publication corresponds to the Common Data Model (CDM) specification of the Baseline Use Case proposed in T.5.2 (WP5) in the BY-COVID project on “COVID-19 Vaccine(s) effectiveness in preventing SARS-CoV-2 infection.”Research Question: “How effective have the SARS-CoV-2 vaccination programmes been in preventing SARS-CoV-2 infections?” Intervention (exposure): COVID-19 vaccine(s) Outcome: SARS-CoV-2 infection Mediator: Vaccination schedule (type of vaccine)Study Design: An observational retrospective longitudinal study to assess the effectiveness of the COVID-19 vaccine(s) in preventing SARS-CoV-2 infections using routinely collected social, health and care data from several countries.A causal model was established using Directed Acyclic Graphs (DAGs) to map domain knowledge, theories and assumptions about the causal relationship between exposure and outcome. The DAG developed for the research question of interest is shown below.Cohort definition: All people, eligible to be vaccinated (from 5 to 115 years old, included) or with, at least, one dose of a SARS-CoV-2 vaccine (any of the available brands) having or not a previous SARS-CoV-2 infection. Inclusion criteria: All people vaccinated with at least one dose of the COVID-19 vaccine (any of the available brands) in an area of residence. Any person eligible to be vaccinated (from 5 to 115 years old, included) with a positive diagnosis (irrespective of the type of test) for SARS-CoV-2 infection (COVID-19) during the period of study. Exclusion criteria: People not eligible for the vaccine (from 0 to 4 years old, included) Study period: From the date of the first documented SARS-CoV-2 infection in each country to the most recent date in which data is available at the time of analysis. Roughly from 01-03-2020 to 30-06-2022, depending on the country.

AB - This publication corresponds to the Common Data Model (CDM) specification of the Baseline Use Case proposed in T.5.2 (WP5) in the BY-COVID project on “COVID-19 Vaccine(s) effectiveness in preventing SARS-CoV-2 infection.”Research Question: “How effective have the SARS-CoV-2 vaccination programmes been in preventing SARS-CoV-2 infections?” Intervention (exposure): COVID-19 vaccine(s) Outcome: SARS-CoV-2 infection Mediator: Vaccination schedule (type of vaccine)Study Design: An observational retrospective longitudinal study to assess the effectiveness of the COVID-19 vaccine(s) in preventing SARS-CoV-2 infections using routinely collected social, health and care data from several countries.A causal model was established using Directed Acyclic Graphs (DAGs) to map domain knowledge, theories and assumptions about the causal relationship between exposure and outcome. The DAG developed for the research question of interest is shown below.Cohort definition: All people, eligible to be vaccinated (from 5 to 115 years old, included) or with, at least, one dose of a SARS-CoV-2 vaccine (any of the available brands) having or not a previous SARS-CoV-2 infection. Inclusion criteria: All people vaccinated with at least one dose of the COVID-19 vaccine (any of the available brands) in an area of residence. Any person eligible to be vaccinated (from 5 to 115 years old, included) with a positive diagnosis (irrespective of the type of test) for SARS-CoV-2 infection (COVID-19) during the period of study. Exclusion criteria: People not eligible for the vaccine (from 0 to 4 years old, included) Study period: From the date of the first documented SARS-CoV-2 infection in each country to the most recent date in which data is available at the time of analysis. Roughly from 01-03-2020 to 30-06-2022, depending on the country.

KW - COVID-19

KW - comparative effectiveness

KW - causal inference

KW - international comparison

KW - SARS-CoV-2

KW - common data model

KW - directed acyclic graph

KW - synthetic data

KW - vaccines

U2 - 10.5281/zenodo.6913046

DO - 10.5281/zenodo.6913046

M3 - Other contribution

PB - Zenodo

ER -

BY-COVID - WP5 - Baseline Use Case: COVID-19 vaccine effectiveness assessment - Common Data Model Specification

Abstract

Keywords

Access to Document

Fingerprint

Projects

BY-COVID: BeYond COVID

Activities

BY-COVID Spring 2024 Baseline Use Case Workshop

Cite this